This page shows what was measured, who it was measured in, and what that does not settle.
What Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf does in the body
RNAWiki has not recorded what this substance changes in the body.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · P188ANX8CK · read 2026-08-29
Where each sentence above came from
No plain explanation of what this changes is stored.
No recorded use is stored in reader language.
No statement of the main limit is recorded.
The four opening statements run to 26 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Recurrence-free survival (RFS)
✗ The study did not show it
Who was studied
NCT06876714
How many people
1524
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1
✗ The study did not show it
Who was studied
NCT05296798
How many people
922
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)
✗ The study did not show it
Who was studied
NCT03493854
How many people
500
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Progression free survival
✗ The study did not show it
Who was studied
NCT05256225
How many people
360
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)
✗ The study did not show it
Who was studied
NCT05415215
How many people
346
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
✗ The study did not show it
Who was studied
NCT04802759
How many people
316
Study design
Phase 1/Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.10 registered measures of this kind. 3 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
reported health related quality of life fact b
Measured
Things only a test, a scale or a device shows.
area under the concentration time curve at steady state
Meaningful
Things that change how a life goes, not only a number.
disease free survival
recurrence free survival
progression free survival
invasive disease free survival between the 2 arms
invasive disease free survival at 3 years
overall survival
progression free survival rate
investigator assessed progression free survival
disease free survival at 4 years
event free survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (26)
duration of dfs
frequency and duration of objective response
acute treatment related toxicity
pcr rate
objective response rate
alive and free from invasive disease
the subgroups who had a pathologic complete response
a pathologic complete response
grade 3 or higher toxicity per study arm
maximum tolerated dose and/or recommended phase ii dose
clinical benefit rate
neutropenia
paclitaxel related neuropathy
response to neoadjuvant chemotherapy determined at surgery
dose limiting toxicities during dose escalation
overall response rate
dose limiting toxicities
safety run in phase 1b/2
incidence of dose limiting toxicities
incidence of adverse events
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
No description of who was studied is recorded.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4, S6.
No source is stored against this line.
What is in the pack
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 11838 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
1 published label names it as an active ingredient. None of them describes this substance alone, so no label text on this page can be attributed to it rather than to a combination.
US prescribing information · 27dd5e6b-72cd-458d-a015-cf4dab5800da · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 27dd5e6b-72cd-458d-a015-cf4dab5800da · read 2026-08-29
107102 marketed supplement labels list this ingredient, classed as botanical with nutrients, multi-vitamin and mineral (mvm) and non-nutrient/non-botanical.
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Phesgo is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: PHESGO is a clear to opalescent, and colorless to slightly brownish solution provided as: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL (80 mg, 40…, recorded as fda label in effect 2026-05-21 in the United States.
US prescribing information · 27dd5e6b-72cd-458d-a015-cf4dab5800da · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
P188ANX8CK
CAS registry number
180288-69-1
ChEMBL
CHEMBL1201585
WHO international nonproprietary name list entry
7637
RxNorm concept
224905
EMA substance identifier
100000089314
DrugBank
DB00072
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✗ Not passed
Every public sentence names a source
The opening statement carries no source: the record holds neither an explanation nor a recorded use.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was BLA761170, approved 20200629 to GENENTECH INC.
This order is fixed in code and does not count clicks or time on the page.
What is not here
7 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (13)
Q2
What did Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's largest trial (6452 people) and its longest (24 years) measure?
6452 people in Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's largest registered study, 24 years in its longest registered window, measuring Changes in Senescence and Secondary Biomarkers, Including TMEM, Mena, and 67LR. ClinicalTrials.gov · 2026-09-01
36 phase2, 19 phase3, 14 phase1, 2 na, 1 early phase1, 1 na or unstated, 1 phase4; NCT04817956; 2045-04-30. Last human test completed 2026, NCT03179904.
Interpretation These counts include studies where Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
36
phase3
19
phase1
14
na
2
early phase1
1
na or unstated
1
2 more recorded rows
phase4
1
Last recorded human testNCT03179904
2026-03-13
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf shown lifespan?
2 recorded entries; human; also "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection", "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection"
Show the evidence
human
NCT06172127
Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
NCT06172127
Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
recorded 2026-09-01 · last checked 2026-09-04
Q6
Did Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf move epigenetic age, and by how much?
epigenetic age: "To examine the associations between pre-treatment epigenetic age acceleration, circulating leukocyte composition, and candidate single nucleotide polymorphisms (SNPs) with cardiotoxicity risk in breast cancer patients receiving trastuzumab." Europe PMC · epigenetic clock search · 2025-05-10
1 recorded sentence; 2025; biomarker
Show the evidence
epigenetic agePMID 40349094
2025; "To examine the associations between pre-treatment epigenetic age acceleration, circulating leukocyte composition, and candidate single nucleotide polymorphisms (SNPs) with cardiotoxicity risk in breast cancer patients receiving trastuzumab."
recorded 2025-05-10 · last checked 2026-09-04
Q7
Which of 16 weeks clinical response, a pathologic complete response and access to drugs for did Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's trials measure?
16 weeks clinical response, a pathologic complete response and access to drugs for lead 38 outcome terms across Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's trials. ClinicalTrials.gov · 2026-09-01
Interpretation pcr rate, area under the concentration time curve at steady state, objective response rate, disease free survival, alive and free from invasive disease and the subgroups who had a pathologic complete response follow.
Show the evidence
duration of dfs
1
frequency and duration of objective response
1
acute treatment related toxicity
1
pcr rate
1
area under the concentration time curve at steady state
1
objective response rate
1
14 more recorded rows
disease free survival
1
alive and free from invasive disease
1
the subgroups who had a pathologic complete response
1
a pathologic complete response
1
grade 3 or higher toxicity per study arm
1
maximum tolerated dose and/or recommended phase ii dose
1
clinical benefit rate
1
neutropenia
1
paclitaxel related neuropathy
1
recurrence free survival
1
response to neoadjuvant chemotherapy determined at surgery
1
dose limiting toxicities during dose escalation
1
overall response rate
1
progression free survival
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's 27 ongoing trials reports first?
27 registered trials of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf are open; earliest completion 2026-04-30. ClinicalTrials.gov · 2026-09-01
Objective response rate (ORR); Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy).; latest 2045-04-30
Show the evidence
Trial
NCT02465060
"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"; n 6452; "Objective response rate (ORR)"; 2026-12-31
NCT02827877
"Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer"; n 18; "Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy)."; 2026-09-25
NCT04266249
"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy"; n 2175; "Recurrence-free survival (RFS)"; 2038-12-31
NCT04285671
"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer"; n 30; "Identification of the recommended phase II dose (R2PD) regimen for combination osimertinib, necitumumab, trastuzumab (ONT) therapy (Phase Ib)"; 2027-12-02
NCT04569747
"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer"; n 393; "Invasive Disease Free Survival at 3 Years"; 2030-09-01
NCT04733118
"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer"; n 393; "3-year recurrence-free interval (3y-RFI)"; 2028-03
14 further recorded trials
NCT04802759
"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer"; n 316; "Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)"; 2029-05-30
NCT04817956
"Improving Public Cancer Care by Implementing Precision Medicine in Norway"; n 3000; "16 weeks clinical response"; 2045-04-30
NCT05020860
"Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer"; n 185; "Change in Clinical Tumor Measurement vs. Pathologic Response"; 2029-11
NCT05041842
"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer"; n 53; "Progression-Free Survival"; 2026-04-30
NCT05132582
"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer"; n 654; "Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"; 2027-09-28
NCT05159245
"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs"; n 250; "Disease control rate"; 2026-11-25
NCT05256225
"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma"; n 360; "Progression free survival"; 2027-10-31
NCT05296798
"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)"; n 922; "Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1"; 2030-12-31
NCT05306041
"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer"; n 170; "Pathologic complete response in the breast and axillary lymph nodes (ypT0/is ypN0)"; 2027-01
NCT05319873
"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer"; n 18; "Maximum tolerated dose (MTD) (Phase Ib)"; 2028-04-01
NCT05332561
"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)"; n 240; "Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery"; 2030-12
NCT05376878
"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis"; n 10; "Percent of patients with quantifiable 64Cu-DOTA-trastuzumab PET uptake"; 2027-04-27
NCT05408845
"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers"; n 146; "Progression free survival (PFS) (HER2-Positive Cohort)"; 2032-07-31
NCT05894239
"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer"; n 230; "Investigator-Assessed Progression-Free Survival (PFS)"; 2032-12-28
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf could settle lifespan?
NCT05041842 measures Progression-Free Survival, reading out 2026-04-30.
12 open trials; n 53; "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer"
Show the evidence
Trial
NCT05041842
"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer"; n 53; "Progression-Free Survival"; 2026-04-30
NCT05132582
"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer"; n 654; "Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"; 2027-09-28
NCT07407920
"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial"; n 120; "Event free survival (EFS)"; 2027-09-30
NCT05256225
"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma"; n 360; "Progression free survival"; 2027-10-31
NCT04569747
"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer"; n 393; "Invasive Disease Free Survival at 3 Years"; 2030-09-01
NCT05332561
"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)"; n 240; "Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery"; 2030-12
6 further recorded trials
NCT05296798
"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)"; n 922; "Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1"; 2030-12-31
NCT05408845
"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers"; n 146; "Progression free survival (PFS) (HER2-Positive Cohort)"; 2032-07-31
NCT05894239
"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer"; n 230; "Investigator-Assessed Progression-Free Survival (PFS)"; 2032-12-28
NCT06439693
"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer"; n 72; "Disease Free Survival at 4 Years (DFS4)"; 2033-03-30
NCT07578116
"Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis"; n 562; "Overall survival (OS) (Cohort A)"; 2033-05-31
NCT04266249
"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy"; n 2175; "Recurrence-free survival (RFS)"; 2038-12-31
Q10
Which 4 trials of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf posted no result?
Posted no result
4 of 4 completed trials
Registrations
NCT00005970, NCT00006089, NCT01434303 and NCT02152943
Completion dates
oldest 2010-01-27; newest 2020-12-14
Show the evidence
Trial
NCT00005970
2010-01-27
NCT00006089
2010-01-31
NCT01434303
2016-02-16
NCT02152943
2020-12-14
Q11
At the median, Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's trials enrolled 160 people — anything larger?
Median enrolment
160
Largest enrolment
6452
Registered trials counted
65
Q12
What do 11838 spontaneous reports say about Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 11838 reaction mentions were counted: diarrhoea 3144; disease progression 1368; ejection fraction decreased 1161; neutropenia 1133. open-targets-adr · CHEMBL1201585 · 2026-06-24
Show the evidence
diarrhoea
3144
disease progression
1368
ejection fraction decreased
1161
neutropenia
1133
myelosuppression
990
febrile neutropenia
950
4 more recorded rows
neuropathy peripheral
944
chills
821
metastases to central nervous system
698
palmar-plantar erythrodysaesthesia syndrome
629
recorded 2026-06-24 · last checked 2026-09-04
Q13
Was Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf studied with exercise?
exercise is named in Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf's label sentences: "Methods Patients were randomized to receive either adjuvant trastuzumab in combination with a training 12-week supervised exercise program in a training group (training group, TG) or trastuzumab alone (control group, CG)." openfda-label+europepmc · 2025-08-08
1 recorded statement; exercise
Show the evidence
exercise
Methods Patients were randomized to receive either adjuvant trastuzumab in combination with a training 12-week supervised exercise program in a training group (training group, TG) or trastuzumab alone (control group, CG).
recorded 2025-08-08 · last checked 2026-09-04
Q14
What is recorded about Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf and mTOR?
"CD24 silencing modulates autophagy and induces apoptosis via Akt/mTOR inhibition, and its combination with trastuzumab exerts potent antitumor effects, offering a promising strategy for HER2 + breast cancer." — where Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf and mTOR appear together. Europe PMC · pathway abstract search · 2026-05-16
"CD24 silencing modulates autophagy and induces apoptosis via Akt/mTOR inhibition, and its combination with trastuzumab exerts potent antitumor effects, offering a promising strategy for HER2 + breast cancer."
autophagyPMID 42141178
"CD24 silencing modulates autophagy and induces apoptosis via Akt/mTOR inhibition, and its combination with trastuzumab exerts potent antitumor effects, offering a promising strategy for HER2 + breast cancer."
mTOR
PMID 40158191
"Clinical trials investigating mTOR inhibitors like sirolimus and combination therapies with agents such as everolimus and trastuzumab are discussed, underscoring their potential in eradicating BCSCs and improving patient outcomes."
PMID 40426308
"This study highlights the potential of combining Hh inhibitors with trastuzumab as a therapeutic strategy for HER2-positive GC by targeting the AKT/mTOR pathway."
autophagy
PMID 40650051
"Here, we investigated how autophagy modulation affects trastuzumab-mediated ADCC in HER2-positive JIMT1 breast cancer cells and NK cells."
PMID 40696560
"Autophagic flux protects HER2+ cancer cells from trastuzumab-induced cytotoxicity, so inhibiting it undermines the resistance phenotype."
IGF-1
"The phosphatidylinositol 3′-kinase (PI3K)/protein kinase B (PKB)/mammalian target of rapamycin pathway (mTOR), cross-talk with estrogen receptors, over-expression of Mucin 1 (MUC1) protein, and involvement of tyrosine kinase receptors like insulin-like growth factor I receptor are key pathways involved in trastuzumab resistance (TR)."
recorded 2026-05-16 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.